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Overview of taxane‑related neuropathy
The National Comprehensive Cancer Network Guide-
lines recommend taxanes for the treatment of early-stage 
and metastatic breast cancer (MBC) [1]. Over the past 
several decades, the efficacy and safety profiles of taxa-
nes—including paclitaxel (Taxol; Bristol-Myers Squibb), 
docetaxel (Taxotere; sanofi-aventis), and nab-paclitaxel 
(Abraxane; Celgene Corporation)—have been well estab-
lished in MBC [2–4]. Neuropathy, a common side effect 
of taxane therapy, is a significant challenge for clinicians 
and patients. Taxane-associated neuropathy can compro-
mise dose delivery and result in dose delays, reductions, or 
discontinuations that ultimately adversely affect treatment 
outcomes [5]. Some patients experience painful and persis-
tent taxane-associated neuropathy that affects their activi-
ties of daily living and overall quality of life [6].
Taxane-associated peripheral neuropathies generally 
comprise sensory or motor neuropathy, depending on 
the type of nerve fibers involved [7]. The mechanism of 
taxane-induced neuropathy has been reported in numer-
ous reviews [8–10]; thus, this review will not go into great 
detail regarding this topic. Briefly, neurons rely on trans-
port and communication spanning the distance between 
the cell body and axons. These processes depend on intact 
and functional cytoskeletal microtubules. The binding of 
taxanes to the β-tubulin subunit of microtubules results in 
stabilization of the microtubule and disruption of micro-
tubule function [11]. It is believed that the inhibition of 
microtubule function affects the structure and function of 
neurons, resulting in clinically apparent neuropathy [10]. 
The degree of neuronal damage depends on several factors, 
such as agent, cumulative dose, and duration of therapy [6]. 
Because of their extended axon length, peripheral nerves 
may be especially sensitive to taxane-induced damage, and 
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the permeability of the blood–nerve barrier also lends itself 
to greater exposure of the sensory nerves to taxanes [7]. 
Taxane-related neuropathy may fall into several categories, 
namely sensory and motor. Sensory neuropathy generally 
manifests as bilateral sensations in the toes and fingertips, 
such as numbness, tingling, and pain; allodynia and dimin-
ished reflexes can also occur [12]. Motor weakness with 
taxane therapy generally affects the extremities [12].
Another important consideration in the development of 
taxane-related neuropathy is the solvent used in formula-
tion, a key difference among the currently available taxa-
nes [2–4]. Paclitaxel is formulated with polyoxyethylated 
castor oil, or Cremophor® EL (recently renamed Kolli-
phor® EL), docetaxel is formulated with polysorbate 80 (or 
TWEEN® 80), and nab-paclitaxel is solvent free, consisting 
of paclitaxel and human serum albumin at a concentration 
similar to the concentration of albumin in the blood [2–4]. 
These differences can result in variations in toxicity pro-
files because the solvents themselves have been associated 
with varying biological effects. With respect to neurotox-
icity, in preclinical studies, axonal swelling, degeneration, 
and demyelination have been observed with Cremophor 
EL [13, 14]. Thus, the damage it induces may be related to 
the persistent neuropathy caused by Cremophor EL-based 
paclitaxel. Polysorbate 80 may also contribute to the neu-
ropathy observed with docetaxel by resulting in degenera-
tion of neuronal vesicles [15]. In clinical studies of patients 
with MBC, severe neuropathy associated with paclitaxel 
and docetaxel persisted longer after discontinuation of 
therapy compared with that associated with nab-paclitaxel 
[16–18]. Severity of taxane-related neuropathy is related to 
a number of factors, including dosing and administration, 
which will be discussed later in this review.
Peripheral neuropathy related to chemotherapy can limit 
treatment for many patients. In a retrospective cohort study 
of patients receiving docetaxel or paclitaxel for nonmeta-
static breast cancer, it was observed that the cumulative 
dose delivered was significantly lower than the planned 
cumulative dose in patients who had a dose reduction/dis-
continuation due to taxane-related chemotherapy (P < .001) 
[19]. In addition, taxane-related neuropathy is often cumu-
lative and can progress after each treatment cycle [20]. 
Cumulative and persistent neuropathy in patients is often 
linked with a decreased ability to receive later lines of 
therapy. As an example, in a phase III trial of patients with 
advanced non-small cell lung cancer, those receiving first-
line paclitaxel plus carboplatin demonstrated increased 
rates of peripheral neuropathy from cycle 4 (20 %) to cycle 
8 (43 %) [21]; the most common reason for not progressing 
to second-line therapy was residual grade 2/3 peripheral 
neuropathy.
Data regarding the long-term effects of taxane-related 
peripheral neuropathy are varied. One study in patients 
who were 1–13 years post-taxane therapy demonstrated 
that paclitaxel- and docetaxel-related peripheral neuropa-
thy completely resolved in only 14 % after treatment dis-
continuation [22]. However, the symptoms of peripheral 
neuropathy in these patients were considered to be well 
tolerated. In a second study of patients who were 6 months 
to 2 years post-adjuvant taxane therapy, 81 % of patients 
evaluated still reported symptoms of peripheral neuropathy, 
with up to 27 % reporting severe symptoms in the hands 
and feet [23]. Chemotherapy-related peripheral neuropathy 
may also be predictive of the development of neuropathic 
pain. A survey of patients who had previously received 
paclitaxel treatment for breast cancer revealed that 27 % of 
those who developed paclitaxel-related neuropathy eventu-
ally developed neuropathic pain [24]. The study suggested 
that monitoring patients who develop peripheral neuropa-
thy on taxane treatment is important, even after treatment is 
discontinued.
The effects of taxane-related neuropathy may differ from 
other microtubule-inhibiting agents used to treat MBC. To 
date, no published head-to-head studies of taxanes and 
single-agent eribulin or ixabepilone exist, but preclinical 
evidence may provide clues about the neuropathic effects 
of these agents. In a preclinical study, mice treated with 
ixabepilone or paclitaxel had significant deficits in nerve 
conduction parameters as well as degenerative changes 
in the pathology of dorsal root ganglia and sciatic nerves, 
whereas mice treated with eribulin mesylate did not expe-
rience significant effects on nerve conduction and expe-
rienced less frequent morphological effects [25]. These 
findings led the authors to conclude that, in mice, eribulin 
mesylate was associated with less neuropathy compared 
with paclitaxel or ixabepilone. A subsequent preclinical 
study demonstrated that paclitaxel was associated with 
additional deleterious effects in mice with preexisting 
paclitaxel-induced peripheral neuropathy, whereas the neu-
ropathic effect with eribulin in these mice was limited [26].
Neuropathy in clinical trials of taxanes in the treatment 
of metastatic breast cancer
The development of taxane-related neuropathy has been 
reported in numerous phase II/III clinical trials (Table 1). A 
major limitation of many studies is the inconsistent report-
ing of neuropathy data; most studies report only grade ≥3 
neuropathy. Taxane-related neuropathy appears to be 
related to dose and/or schedule [6, 10, 27–29].
Neuropathy in trials of paclitaxel
In a phase III study of paclitaxel (± trastuzumab) admin-
istered weekly versus every 3 weeks (q3w) for the first- or 
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second-line treatment of MBC [Cancer and Leukemia Group 
B (CALGB) 9840], the weekly schedule produced a signifi-
cantly higher overall response rate (ORR) versus the q3w 
schedule (42 vs 29 %; P = .004) and a longer median time 
to progression (TTP; 9 vs 5 months; P < .0001) and median 
overall survival (OS; 24 vs 12 months; P = .0092) [29]. The 
weekly dose was decreased from 100 to 80 mg/m2 because 
of a 30 % incidence of sensory neuropathy [29]. Both 
Table 1  Taxane-induced peripheral neuropathy incidence in phase II/III clinical trials of metastatic breast cancer
NR not reported, q3w every 3 weeks, qw every week
a
  Sensory versus motor not delineated
Study Population (no.) Taxane Dosage and schedule Sensory neuropathy,  %
Grade 2 Grade 3 Grade 4
Albain et al. [81] Metastatic, previously treated 
(521)
Paclitaxel 175 mg/m2 q3w 18 4–5 <1
Andersson et al. [82] Metastatic or locally 
advanced, previously treated 
(139)
Docetaxel 100 mg/m2 q3w 19 31 0
Fountzilas et al. [83] Metastatic, previously treated 
(131)
Paclitaxel (plus carboplatin) 175 mg/m2 q3w NR 5a (grade 3 or 
higher)
Metastatic, previously treated 
(134)
Docetaxel 75 mg/m2 q3w NR 0a (grade 3 or 
higher)
Metastatic, previously treated 
(133)
Paclitaxel 80 mg/m2 weekly NR 8a (grade 3 or 
higher)
Gradishar et al. [17] Metastatic, previously treated 
(229)
nab-Paclitaxel 260 mg/m2 q3w NR 10 0
Metastatic, previously treated 
(225)
Paclitaxel 175 mg/m2 q3w NR 2 0
Gradishar et al. [16] Metastatic first-line (76) nab-Paclitaxel 300 mg/m2 q3w NR 21 0
Metastatic first-line (76) nab-Paclitaxel 100 mg/m2 qw NR 9 0
Metastatic first-line (74) nab-Paclitaxel 150 mg/m2 qw NR 22 0
Metastatic first-line (74) Docetaxel 100 mg/m2 q3w NR 12 0
Miles et al. [84] Metastatic or locally 
advanced, previously treated 
(231)
Docetaxel 100 mg/m2 q3w NR 2 (grade 3 or 
higher)
Miller et al. [85] Metastatic or locally 
advanced, previously treated 
(346)
Paclitaxel 90 mg/m2 weekly for 3 of 
4 weeks
NR 17 <1
Rivera et al. [28] Metastatic or locally 
advanced, previously treated 
(59)
Docetaxel 75 mg/m2 q3w NR 10 (grade 3 or 
higher)
Metastatic or locally 
advanced, previously treated 
(59)
Docetaxel 35 mg/m2 weekly every 3 of 
4 weeks
NR 5 (grade 3 or 
higher)
Seidman et al. [29] Metastatic, previously treated 
(225)
Paclitaxel 175 mg/m2 q3w 21 12 0
Metastatic, previously treated 
(346)
Paclitaxel 80–100 mg/m2 weekly 21 24–30 <1
Valero et al. [86] Metastatic, previously treated 
(131)
Docetaxel 100 mg/m2 q3w 58 (grades 1–4); 3 (grade 
3 or higher)
Metastatic, previously treated 
(131)
Docetaxel (plus carboplatin) 75 mg/m2 q3w 46 (grades 1–4); 1 (grade 
3 or higher)
Winer et al. [30] Metastatic, previously treated 
(158)
Paclitaxel 175 mg/m2 q3w 57 (grades 1–4); 7 (grade 
3 or higher)
Metastatic, previously treated 
(156)
Paclitaxel 210 mg/m2 q3w 73 (grades 1–4); 19 
(grade 3 or higher)
Metastatic, previously treated 
(155)
Paclitaxel 250 mg/m2 q3w 83 (grades 1–4); 33 
(grade 3 or higher)
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treatment arms had similar incidences of grade 2 neuropa-
thy (21 %), but the weekly schedule of paclitaxel produced 
twice as much grade 3 sensory neuropathy (24 %) versus the 
q3w schedule (12 %) (P = .0046 for grade ≥2). In the same 
study, the weekly arm was associated with a significantly 
higher rate of grade 2 and 3 motor neuropathy (8 and 9 %, 
respectively) versus the q3w arm (4 and 5 %, respectively) 
(P = .013 for grade ≥2). CALGB Protocol 9342 assessed 
the efficacy and safety of three paclitaxel doses adminis-
tered q3w: 175, 210, and 250 mg/m2 in patients with MBC 
who had received ≥1 prior chemotherapy regimen for meta-
static disease [30]. No differences were observed in ORR 
between the arms (21–26 %; P = NS) or in median OS (11–
14 months; P = NS), but the 250-mg/m2 dose demonstrated 
a slightly longer median TTP versus the 210- and 175-mg/
m2 doses (4.9 vs 4.1 vs 3.9 months, respectively; P = .045). 
The incidence of grade 3/4 sensory and motor neuropathy 
was dose related. The 250-mg/m2 dose produced the high-
est rate of grade 3/4 sensory and motor neuropathy (33 and 
14 %, respectively), followed by the 210-mg/m2 dose (19 
and 11 %, respectively) and the 175-mg/m2 dose (7 and 
5 %, respectively). Interestingly, the incidences of grade 1/2 
sensory neuropathy appeared to be higher in the 175- and 
210-mg/m2 arms than in the 250-mg/m2 arm [79 vs 57 vs 
35 %, respectively; P = not reported (NR)], as did the inci-
dences of grade 1/2 motor neuropathy (89 vs 83 vs 79 %, 
respectively; P = NR).
Neuropathy in trials of docetaxel
A phase III study assessed the efficacy and safety of doc-
etaxel 75 mg/m2 q3w versus docetaxel 35 mg/m2 weekly for 
3 weeks followed by 1 week of rest (qw 3/4) in patients who 
had received ≥one prior chemotherapy regimen for meta-
static disease [28]. The q3w schedule demonstrated a numeri-
cally higher ORR (36 vs 20 %; P = NR), a similar median 
progression-free survival (PFS) (5.7 vs 5.5 months; P = NS), 
and OS (18.3 vs 18.6 months; P = NS), but more grade 3/4 
neuropathy versus the weekly schedule (10 vs 5 %; P = NR). 
In a phase II study of patients with MBC who had received 
≥one prior chemotherapy regimen for metastatic disease, 
docetaxel 40 mg/m2 weekly versus docetaxel 100 mg/m2 
q3w, respectively, demonstrated similar ORRs (34 vs 33 %; 
P = NR) and median TTPs (5.7 vs 5.3 months; P = NR) and 
a longer median OS (29.1 vs 20.1 months; P = NR) [31]. 
Again, the q3w schedule demonstrated a higher incidence 
of grade 3/4 neurotoxicity (17 vs 2 %; P = NR), and more 
patients discontinued treatment in the q3w arm versus the 
weekly arm because of neurotoxicity (12 vs 2 %; P = NR). 
In a phase III trial of patients with anthracycline-pretreated 
MBC, no differences were observed between docetaxel 
36 mg/m2 weekly and docetaxel 100 mg/m2 q3w in ORR (25 
vs 26 %; P = NR), median PFS (4.5 vs 5.1 months; P = NS), 
and OS (7.8 vs 9.9 months; P = NS); however, the median 
time to treatment failure was significantly longer in the q3w 
arm (3.2 vs 4.0 weeks; P = .015) [32]. Grade 3/4 motor neu-
ropathy was observed in 6.5 % of patients in the q3w arm 
versus 1.3 % of patients in the weekly arm, and 2.6 % of 
patients withdrew as a result of motor neuropathy in the q3w 
arm versus none in the weekly arm.
Neuropathy in trials comparing paclitaxel with docetaxel
In a phase III study of paclitaxel 175 mg/m2 q3w versus 
docetaxel 100 mg/m2 q3w in patients with MBC that had 
progressed after an anthracycline-based regimen, doc-
etaxel produced a significantly longer median OS (15.4 vs 
12.7 months; P = .03), a significantly longer median TTP 
(5.7 vs 3.6 months; P < .0001), and a numerically higher 
ORR (32 vs 25 %; P = NS) versus paclitaxel [33]. Doc-
etaxel versus paclitaxel produced a higher incidence of 
grade 3/4 neurosensory toxicity (7 vs 4 %; P = .08) and 
neuromotor toxicity (5 vs 2 %; P = .001) and more all-
grade neurosensory toxicity (64 vs 59 %; P = NR) and 
neuromotor toxicity (28 vs 13 %; P = NR). A greater per-
centage of patients treated with docetaxel versus paclitaxel 
discontinued therapy because of neurosensory toxicity (8 
vs 4 %) and neuromotor toxicity (5 vs 1 %).
Neuropathy in trials comparing nab-paclitaxel with other 
taxanes
In the phase III study of nab-paclitaxel 260 mg/m2 versus 
paclitaxel 175 mg/m2 (both q3w), as ≥first-line therapy for 
patients with MBC, nab-paclitaxel produced a significantly 
longer ORR (33 vs 19 %; P = .001) and a significantly 
longer median TTP (5.3 vs 3.9 months; P = .006) [17]. No 
grade 4 sensory or motor neuropathy was observed in either 
arm; however, grade 3 sensory neuropathy was observed 
in 10 % of patients treated with nab-paclitaxel versus 2 % 
treated with paclitaxel (P < .001). The higher rate of neu-
ropathy with nab-paclitaxel was not unexpected, because the 
actual delivered paclitaxel dose was 49 % higher with nab-
paclitaxel versus paclitaxel (mean ± SD: 85.13 ± 3.118 vs 
57.02 ± 3.008 mg/m2 per week, respectively). The incidence 
of grade 3 neuropathy observed with nab-paclitaxel 260 mg/
m2 q3w was lower than that reported with a similar dose and 
schedule of paclitaxel in the CALGB 9342 trial. In that trial, 
32 % of patients who received paclitaxel 250 mg/m2 q3w 
experienced grade 3 sensory neuropathy [30].
A randomized phase II study compared the efficacy and 
safety of various doses of qw 3/4 and q3w nab-paclitaxel 
versus docetaxel q3w as first-line treatment for MBC [27]. 
nab-Paclitaxel 150 mg/m2 qw 3/4 resulted in the long-
est median OS (33.8 months) followed by nab-paclitaxel 
300 mg/m2 q3w (27.7 months), docetaxel 100 mg/m2 
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q3w (26.6 months), and nab-paclitaxel 100 mg/m2 qw 3/4 
(22.2 months) [16]. Furthermore, treatment with nab-pacli-
taxel 100 mg/m2 qw 3/4, 150 mg/m2 qw 3/4, and 300 mg/
m2 q3w resulted in a significantly higher investigator-
assessed ORR versus docetaxel (63, 74, and 46 % vs 39 %; 
P < .001 overall); independently assessed ORR was also 
higher with the nab-paclitaxel 100 mg/m2 qw 3/4, 150 mg/
m2 qw 3/4, and 300 mg/m2 q3w arms versus the docetaxel 
arm (34, 36, and 28 % vs 26 %; P = NS) [27]. Nonsig-
nificant differences in the incidence of neuropathy existed 
between the various doses/schedules of nab-paclitaxel and 
docetaxel [16]. No grade 4 neuropathy was reported, but 
nab-paclitaxel at 300 mg/m2 q3w and 150 mg/m2 qw 3/4 
resulted in the highest rates of sensory neuropathy (21 and 
22 % of patients, respectively) versus 12 % of patients in 
the docetaxel arm and 9 % of patients in the nab-paclitaxel 
100 mg/m2 qw 3/4 arm (P = NS overall) [16].
Neuropathy in recent trials comparing nab-paclitaxel 
combinations with other taxane combinations
Rates of neuropathy associated with taxanes or ixabepi-
lone plus bevacizumab for the treatment of MBC from a 
large cooperative group trial were reported [34]. The phase 
III CALGB 40502 trial compared the efficacy and safety of 
nab-paclitaxel 150 mg/m2 qw 3/4 plus bevacizumab 10 mg/
kg q2w with either paclitaxel 90 mg/m2 qw 3/4 or ixabepi-
lone 16 mg/m2 qw 3/4, both combined with the same dose/
schedule of bevacizumab. A protocol amendment made the 
use of bevacizumab optional after the withdrawal of Food 
and Drug Administration approval in March 2011, but 98 % 
of patients in the study received bevacizumab. The median 
PFS (primary endpoint) was not statistically significantly dif-
ferent between the nab-paclitaxel (n = 271) and paclitaxel 
arms (n = 283) (9.2 vs 10.6 months; P = .12) and neither 
was the median OS (27 vs 26 months; P = .92). Rates of 
grade 2 neuropathy were similar between the nab-paclitaxel 
and paclitaxel arms (27 % for both) as were rates of grade 
4 neuropathy (1 vs <1 %). However, a higher incidence of 
grade 3 neuropathy was observed in patients receiving nab-
paclitaxel versus those receiving paclitaxel (24 vs 16 %) 
leading to a significantly higher rate of grade ≥3 neuropathy 
for nab-paclitaxel versus paclitaxel (25 vs 16 %; P = .012). 
Complete results from this study are eagerly anticipated. 
Similarly, in a phase II study of three different doses/sched-
ules of nab-paclitaxel (260 mg/m2 q3w, 260 mg/m2 q2w with 
filgrastim, or 130 mg/m2 qw) with bevacizumab (10 mg/
kg q2w or 15 mg/kg q3w) in patients with MBC, the ORRs 
(primary endpoint) were 45, 41, and 46 %, respectively, and 
rates of grade ≥3 neuropathy were 33, 56, and 46 %, respec-
tively [35]. These findings suggest that nab-paclitaxel plus 
bevacizumab is active in MBC; however, the optimal sched-
ule/dose of nab-paclitaxel requires further evaluation.
Time to onset and improvement of neuropathy
Most phase II/III studies of taxanes in MBC have not 
reported time to onset or improvement of neuropathy, 
which are important factors affecting treatment decisions. 
One major reason for this may be that many patients have 
a preexisting level of neuropathy at enrollment because 
of prior chemotherapy treatment; thus, it may be difficult 
to distinguish preexisting neuropathy from that brought 
on by therapy. In one study of weekly paclitaxel 80 mg/
m2 in patients with MBC who received ≤2 prior chemo-
therapy regimens for metastatic disease, 69 % of patients 
developed neuropathy and 9 % of patients developed grade 
3 neuropathy (no grade 4) [36]. The median time to onset 
of grade 2/3 neuropathy in that study was approximately 
4.7 months. In another study of paclitaxel 200–250 mg/m2 
q3w, symptoms of neuropathy occurred after an average of 
1.7 cycles in 84 % of patients [37].
Rapid improvement in neuropathic symptoms may allow 
patients to resume treatment more quickly and is important 
to note when considering timing, choice, and dose/schedule 
of later lines of therapy. Studies of nab-paclitaxel in MBC 
have reported time to improvement in neuropathy, and it 
is generally faster than with paclitaxel or docetaxel. In the 
study by Forsyth et al. of paclitaxel 200–250 mg/m2 q3w in 
previously treated patients with MBC, follow-up data were 
obtained in 19 % of patients; peripheral neuropathy had 
improved or resolved in all of these patients 1–6 months 
after treatment stopped [37]. In the phase II study by 
Gradishar et al. of nab-paclitaxel (100 and 150 mg/m2 
qw 3/4 and 300 mg/m2 q3w) versus docetaxel 100 mg/m2 
q3w for the first-line treatment of MBC, the median time 
to improvement in grade 3 neuropathy to grade ≤2 was 
20–22 days with nab-paclitaxel compared with 41 days 
with docetaxel [16]. In the phase III study of nab-pacli-
taxel (260 mg/m2 qw) versus paclitaxel (175 mg/m2 qw) 
in patients with MBC by Gradishar et al., the median time 
to improvement in grade 3 neuropathy to grade ≤2 was 
22 days for nab-paclitaxel and 79 days for paclitaxel [18]. 
Because peripheral neuropathy associated with nab-pacli-
taxel treatment appears to improve more quickly than with 
treatment with either paclitaxel or docetaxel, patients previ-
ously receiving nab-paclitaxel who have seen improvement 
in their peripheral neuropathy theoretically could progress 
to later lines of therapy more quickly.
Predictors of taxane‑induced neuropathy
Recent studies have identified potential molecular predic-
tors of taxane-induced neuropathy. In the Eastern Coopera-
tive Oncology Group (ECOG) 5103 study of women with 
early-stage breast cancer treated with weekly paclitaxel 
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(± bevacizumab) in the adjuvant setting, a genome-wide 
association study showed that single nucleotide polymor-
phisms (SNPs) in two genes—RWDD3 and TECTA—were 
significantly associated with time to onset of neuropathy 
(P < 5 × 10−7) [38], but this association could not be con-
firmed in a recent study of Scandinavian patients with ovar-
ian cancer [39]. Another genome-wide association study in 
the CALGB 40101 trial showed a SNP in the gene FGD4 
that was associated with the early onset of peripheral neu-
ropathy in patients treated with paclitaxel [40]. In the same 
study, other SNPs in the EPHA5 and FZD3 genes were 
also identified as being potential risk factors for the onset 
and severity of peripheral sensory neuropathy. In another 
study, patients with ABCB1 variants were potentially more 
likely to develop paclitaxel-induced peripheral neuropathy 
than were those with the wild-type allele (P = .09) [41]. 
An association between a GSTP1 polymorphism and doc-
etaxel-induced peripheral neuropathy has also been iden-
tified [42]. Patients with the 105Ile/105Ile GSTP1 genotype 
had a significantly greater risk of developing more severe 
docetaxel-induced peripheral neuropathy than did those 
with other GSTP1 genotypes (P = .03). Finally, in breast 
cancer patients treated with paclitaxel, CYP2C8*3 sta-
tus was significantly associated with an increased risk of 
paclitaxel-induced neuropathy (P = .006); each CYP2C3*8 
allele approximately doubled a patient’s risk of developing 
grade ≥2 neuropathy (P = .004) [43].
Age, race, and comorbid conditions, such as diabetes, 
may also be associated with an increased risk of developing 
neuropathy. The results of the ECOG 5103 study showed 
a significant association between neuropathy and age 
(12.9 % increase with each 10 years; P = .004) and Afri-
can-American race (P = 4.5 × 10−11) [38]. In an analysis 
of the ECOG 1199 study of patients with breast cancer who 
received adjuvant taxane-containing therapy, hypergly-
cemia and obesity were associated with an increased risk 
of neuropathy, and African-American race demonstrated a 
trend toward an increased risk of neuropathy with weekly 
paclitaxel [44]. Although age was associated with an 
increased risk of neuropathy in the ECOG 5103 study [38], 
this trend was not observed in the ECOG 1199 study [44]. 
In that study, the development of neuropathy was found 
not to be predictive of survival outcomes. Furthermore, 
approximately half of all patients with diabetes are at risk 
of developing diabetic peripheral neuropathy [45, 46]. It is 
well known that high blood glucose can damage peripheral 
nerves; thus, patients with diabetes who are treated with 
chemotherapy agents associated with peripheral neuropa-
thy, such as taxanes, may be at greater risk for developing 
chemotherapy-related peripheral neuropathy. While data 
are limited, some reports have suggested an increased risk 
of chemotherapy-related peripheral neuropathy or a wors-
ening of preexisting neuropathy in patients with diabetes 
[47, 48]. With respect to taxane-based therapy, in an explor-
atory analysis of a phase III trial in patients with advanced 
non-small cell lung cancer, those with diabetes who were 
treated with nab-paclitaxel plus carboplatin had a 4 % 
higher rate of grade ≥3 peripheral neuropathy (7 %) than 
did the intent-to-treat population (3 %), while patients with 
diabetes who were treated with paclitaxel plus carboplatin 
had a 12 % higher rate of grade ≥3 peripheral neuropathy 
(23 %) compared with the intent-to-treat population (11 %) 
[49, 50]. While this finding is interesting, because of the 
exploratory nature of this analysis, no conclusions can be 
definitively drawn about whether patients with diabetes are 
at increased risk of developing peripheral neuropathy with 
nab-paclitaxel or paclitaxel regimens.
Management of neuropathy
Early recognition of the signs and symptoms of taxane-
related neuropathy is critical for appropriate management 
and improved outcomes. Typically, taxane-related neurop-
athy is managed with dose delays and/or reductions. For 
example, it is recommended that, for patients experiencing 
grade 3 neuropathy, the dose of nab-paclitaxel should be 
held until resolution to grade 1 or 2, followed by a dose 
reduction for all subsequent doses of nab-paclitaxel [2]. 
A 20 % dose reduction is recommended for all subse-
quent courses in patients receiving paclitaxel who develop 
severe peripheral neuropathy, and discontinuation is recom-
mended in patients receiving docetaxel who develop grade 
3/4 neuropathy [3, 4]. Numerous studies of interventions 
for the management of neuropathy exist; however, for the 
most part, many of these interventions have not demon-
strated a meaningful improvement in neuropathic symp-
toms, and some agents have even worsened symptoms of 
chemotherapy-induced neuropathy compared with placebo 
(Table 2) [51–56]. Several of these interventions have been 
covered in previous reviews of taxane-related neuropathy 
[12, 57]. This review will focus only on recent highlights 
in this area.
Results of the phase III CALGB 170601 study of dulox-
etine 60 mg daily, in patients who developed chemother-
apy-induced neuropathic pain after taxane or oxaliplatin 
treatment, showed that the drug was significantly more 
effective than placebo at reducing taxane-related neuro-
pathic pain symptoms (P = .003) [58]. Patients treated 
with duloxetine also experienced a significant decrease 
in the amount of pain that interfered with daily function-
ing compared with placebo (P = .01). Furthermore, 41 % 
of patients treated with duloxetine reported a decrease 
in numbness and tingling in the feet compared with only 
23 % of patients treated with placebo (P = NR); this trend 
was not observed for numbness and tingling in the hands 
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(P = NR). Although the safety profile of duloxetine is gen-
erally considered to be acceptable, it should not be admin-
istered with drugs that inhibit serotonin reuptake, CYP 
P450 2D6 substrates, warfarin, or nonsteroidal anti-inflam-
matory drugs.
Another study found that omega-3 fatty acids may offer 
protection against paclitaxel-induced peripheral neuropa-
thy [59]. In that study, patients with breast cancer received 
omega-3 fatty acid pearls or placebo during paclitaxel treat-
ment. For 1 month after treatment, the patients were evalu-
ated by using the reduced total neuropathy score; 70 % of 
the group that received omega-3 fatty acids did not develop 
peripheral neuropathy (any grade) compared with 41 % 
of patients in the placebo group (P = .029); no significant 
difference in the severity of peripheral neuropathy was 
observed between the 2 groups.
Other agents are in the early stages of assessment for the 
treatment or prevention of chemotherapy-related periph-
eral neuropathy. A recent preclinical study demonstrated 
that coadministration of metformin protected mice against 
chemotherapy-induced peripheral neuropathy [60]. The 
study found that cisplatin treatment led to the loss of 
intraepidermal nerve fibers in the paws and that metformin 
prevented this phenomenon. A separate preclinical study 
demonstrated that concurrent administration of interleu-
kin-6 and cisplatin, vincristine, or paclitaxel in rodents 
prevented electrophysical abnormalities associated with 
neuropathy as well as pathological changes in peripheral 
nerves [61]. Treatment with interleukin-6 did not appear to 
affect the antitumor activity of these agents or affect tumor 
growth. Whether or not these preclinical findings will trans-
late to humans remains to be seen.
Nonpharmaceutical methods of neuropathy manage-
ment are also being studied. A case report of a patient with 
esophageal carcinoma who developed grade 2 peripheral 
neuropathy with docetaxel plus cisplatin demonstrated 
that manual therapy (i.e., massage) completely resolved 
the patient’s neuropathic symptoms [62]. In uncontrolled 
Table 2  Select recent clinical studies of agents used to manage chemotherapy-induced peripheral neuropathy
BAK baclofen, amitriptyline, and ketamine, CONcePT Combined Oxaliplatin Neurotoxicity Prevention Trial
Agent/study N Study type/findings
Gabapentin
 Rao et al. [52] 115 Phase III, randomized, double-blind study; no benefit of gabapentin versus placebo
Duloxetine
 Lavoie Smith et al. [87] 231 Phase III, randomized, double-blind study; duloxetine significantly reduced neuropathic  
pain outcomes versus placebo (P = .003)
Amitriptyline
 Kautio et al. [51] 114 Randomized, double-blind study; no benefit of amitriptyline versus placebo
Lamotrigine
 Rao et al. [53] 125 Phase III, randomized, double-blind study; no benefit of lamotrigine versus placebo
Acetyl-l-carnitine
 Hershman et al. [54] 409 Phase III, randomized, double-blind study; nonsignificantly decreased neuropathic symptoms at 
week 12, but significantly increased symptoms by week 24 versus placebo (P = .01)
Omega-3 fatty acids
 Ghoreishi et al. [59] 69 Randomized, double-blind study; significantly decreased incidence of peripheral neuropathy  
with omega-3 fatty acid pearls (P = .029) and nonsignificantly decreased peripheral neuropathy 
severity versus placebo
Vitamin E
 Kottschade et al. [88]
207 Phase III, randomized, double-blind study; no significant difference in time to onset of neuropathy, 
dose reductions as a result of neuropathy, or incidence of grade ≥2 sensory neuropathy with  
vitamin E versus placebo
Calcium and magnesium
 Grothey et al. [89] 102 Phase III, randomized, double-blind study; calcium and magnesium significantly decreased the  
incidence of grade ≥2 sensory neuropathy versus placebo (P = .038); this trial was terminated 
early because of a decreased response rate in the calcium and magnesium arm of the CONcePT 
study, which was also terminated early [90]
Topical BAK gel
 Barton et al. [91] 208 Phase III, randomized, double-blind study; BAK demonstrated a nonsignificant improvement in 
symptoms of sensory neuropathy and a significant improvement in motor neuropathy versus pla-
cebo (P = .021)
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studies, treatment with a noninvasive electro-analgesia 
device, referred to as “Scrambler” therapy, demonstrated 
benefit for painful chemotherapy-induced peripheral neu-
ropathy [63]; however, the results of other studies have 
been mixed. In a randomized controlled study of patients 
with neuropathic pain, Scrambler therapy appeared to be 
more beneficial than guideline-based drug management 
at relieving chronic neuropathic pain as assessed with 
a visual analog scale (P < .0001) [64]. However, Scram-
bler therapy failed to show any significant difference from 
sham therapy in pain scores in a recent randomized dou-
ble-blind study of patients with neuropathic pain [65]. Fur-
ther studies of Scrambler therapy in various solid tumors 
are ongoing. Several case series, case reports, and other 
small studies have demonstrated improvement in neuro-
pathic symptoms with acupuncture [66–69]. A phase II 
randomized trial that will assess the effects of acupunc-
ture in preventing dose reductions due to chemotherapy-
induced peripheral neuropathy in patients with breast 
cancer is currently ongoing (ClinicalTrials.gov identifier 
NCT01881932).
Neuropathy assessment tools
Many times, neuropathy is underrecognized and under-
reported by physicians compared with patients [70–72]. 
Furthermore, neuropathy induced by taxanes is gener-
ally quantified in clinical studies by using toxicity grad-
ing scales [e.g., National Cancer Institute Common Toxic-
ity Criteria for Adverse Events (NCI CTCAE)], and these 
scales often have suboptimal reliability, sensitivity, and 
validity [71, 73, 74]. Therefore, patient-reported neuropa-
thy tools are important for assessing the development and 
improvement in chemotherapy-induced peripheral neu-
ropathy, and more prospective studies using these types of 
tools in trials of MBC are critically needed. A major advan-
tage to these patient-reported tools is the ability to capture 
treatment effects over time, even after treatment has been 
completed. This is important for patients receiving taxane 
therapy, because peripheral neuropathy with some taxanes 
can persist for an extended period of time.
Select patient-reported tools for use in assessing tax-
ane-induced neuropathy are shown in Table 3. Numerous 
patient-reported tools have been validated [75]; however, 
the Functional Assessment of Cancer Therapy (FACT)-
Taxane tool is the only taxane-specific tool for assess-
ing patient-reported taxane-related symptoms, includ-
ing neuropathy [76]. FACT-Taxane consists of a 16-item 
FACT-General (FACT-G) and an 11-item taxane sub-
scale that allow for the evaluation of disease symptoms 
and taxane-related toxicity [77]. The FACT-Ntx scale is 
another iteration of the FACT family of tools that spe-
cifically measures neurotoxicity produced by chemother-
apy [77]. The FACT-Ntx is an 11-item questionnaire that 
focuses solely on chemotherapy-induced neurotoxicity; 
it is commonly used in combination with the FACT-
G scale as part of the FACT/Gynecologic Oncology 
Group Neurotoxicity scale. In one study, the addition 
of paclitaxel to cisplatin plus doxorubicin in patients 
with advanced endometrial cancer produced more neu-
ropathy and lower FACT-Ntx scores (indicating worse 
Table 3  Patient-reported tools used to assess peripheral neuropathy in clinical trials
EORTC European Organisation for the Research and Treatment of Cancer, FACT Functional Assessment of Cancer Therapy, FACT/GOG-Ntx 
FACT/Gynecologic Oncology Group Neurotoxicity, QLQ-CIPN20 Quality of Life Questionnaire–Chemotherapy-Induced Peripheral Neuropa-
thy 20
Measure Description
FACT/GOG-Ntx subscale [73, 74, 77, 92] 11-Item neurotoxicity subscale of FACT-General
Scoring: 0–4, with 0 representing “not at all” and 4 representing “very much”
Example item: I feel discomfort in my hands.
QLQ-CIPN20 [80] 20-Item self-report questionnaire designed to supplement the EORTC Quality Of Life 
Questionnaire
Scoring: 1–4, with 1 representing “not at all” and 4 representing “very much.”
Example item: during the past week, did you have tingling toes or feet?
Chemotherapy-Induced Peripheral Neuropathy Tool [79] 50-Item self-report questionnaire
Scoring: 0–10, with 0 representing “not at all” and “never” and 10 representing “com-
pletely,” “always,” or “extremely”
Example item: at its worst, how severe is the numbness in the hands?
Patient Neurotoxicity Questionnaire [70] 2 Subjective items that assess sensory and motor neuropathy
Scoring: A (no neuropathy) to E (severe neuropathy)
Example item: I have no numbness, pain, or tingling in my hands or feet.
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neuropathy) compared with doxorubicin plus cisplatin 
alone (P < .001), and the differences were still signifi-
cant after 6 months (P = .014) [78].
The Chemotherapy-Induced Peripheral Neuropathy 
Assessment Tool (CIPNAT) was recently developed but 
has not yet been validated in any studies to date [79]. 
The CIPNAT is a 36-item tool that evaluates the occur-
rence, severity, distress, and frequency of nine neuro-
pathic symptoms and 14 items that evaluate neuropathic 
interference with activities. Another tool, the Patient 
Neurotoxicity Questionnaire (PNQ), contains only two 
items to assess the incidence and severity of sensory and 
motor neuropathy [70]. It was prospectively assessed in 
a phase III study of patients with breast cancer receiv-
ing adjuvant therapy with a taxane [70]. The PNQ scores 
were compared with FACT-Ntx, FACT-G, and NCI 
CTCAE scores, and the results showed a strong correla-
tion between the PNQ and the FACT-Ntx but only a weak 
correlation between the PNQ and the FACT-G. The PNQ 
scores were significantly correlated with the NCI CTCAE 
sensory neuropathy scores but not with the motor neu-
ropathy scores; the physician-assessed scores were lower 
than the patient-reported scores in this study. Finally, the 
Quality of Life Questionnaire (QLQ)–Chemotherapy-
Induced Peripheral Neuropathy (CIPN) 20 scale is a 
20-item patient-reported tool that supplements the Euro-
pean Organization for Research and Treatment of Cancer 
QLQ questionnaire [80]. The QLQ-CIPN20 recently dem-
onstrated good validity and reliability scores in a stand-
ardization study performed by the Chemotherapy-Induced 
Peripheral Neuropathy Outcome Measures Study Group, 
and further studies are planned to evaluate the responsive-
ness aspects of this tool [73].
Conclusions and future perspectives
Although newer targeted agents are being developed, tax-
anes remain a standard of care therapy for patients with 
MBC. Neuropathy is an important, dose-limiting, painful, 
and often irreversible toxicity associated with taxane ther-
apy. Thus, there exists a need to balance taxane efficacy 
and toxicity. Fully understanding the differences in the 
development and improvement in neuropathy between the 
taxanes is highly important for making treatment decisions 
and proactively managing patients with MBC on taxane 
therapy.
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